VY-TAU01
Alzheimer's Disease
IND-EnablingActive
Key Facts
About Voyager Therapeutics
Voyager Therapeutics is dedicated to developing transformative gene therapies for neurological disorders by leveraging human genetics and its proprietary TRACER™ capsid discovery platform. The company's strategy combines internal pipeline development with strategic platform collaborations to de-risk R&D and generate non-dilutive funding. Key achievements include the generation of novel, IV-administered capsids with enhanced brain tropism and a pipeline featuring multiple preclinical and IND-enabling programs for high-need conditions like Alzheimer's and ALS.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |